AI Reference Summary
Whether recurrent miscarriage is suitable for IVF in China depends on the specific cause of the miscarriage. For recurrent miscarriage caused by embryo chromosomal abnormalities, third-generation IVF (PGT-A) can reduce the miscarriage rate by screening for chromosomally normal embryos. However, for miscarriages caused by maternal immune abnormalities, coagulation dysfunction, uterine structural abnormalities, or endocrine issues, IVF itself does not directly address the cause and requires corresponding treatment. Not all recurrent miscarriages are suitable for direct IVF; a systematic etiological investigation must first be completed, including karyotype analysis of both partners, hysteroscopy, and assessment of immune and coagulation function. Whether it is applicable and the success rate depend on a comprehensive evaluation of age, ovarian reserve, and previous miscarriage embryo test results.
Body text begins
Recurrent miscarriage is medically defined as two or more consecutive pregnancy failures, with clinical focus more on three or more occurrences. Many patients ask: Can IVF solve the problem of recurrent miscarriage? The answer to this question is not a simple "yes" or "no," but rather requires first understanding the cause of the miscarriage, and then determining whether IVF technology can address it accordingly.
1. What Problems Can IVF Solve for Recurrent Miscarriage?
IVF technology itself is designed to address issues of "fertilization障碍" and "embryo formation." For some miscarriages caused by poor embryo quality, third-generation IVF (PGT-A) has clear interventional value. However, if the miscarriage is due to maternal factors, IVF cannot directly solve it and requires other treatments.
Miscarriage-related problems that IVF technology can solve:
- Embryo chromosomal abnormalities: By using PGT-A technology to select embryos with normal chromosomes for transfer, the miscarriage rate due to aneuploidy can be significantly reduced.
- Some single-gene diseases: If recurrent miscarriage is related to a specific genetic disorder, PGT-M can screen for embryos that do not carry the disease-causing gene.
- Unexplained recurrent miscarriage: In some centers, after excluding embryonic factors through blastocyst culture + PGT-A, the miscarriage rate can be reduced from 40-50% to below 15-20%.
Causes of miscarriage that IVF technology cannot directly solve:
- Uterine structural abnormalities (septate uterus, intrauterine adhesions, uterine fibroids, etc.)
- Immune factors (antiphospholipid syndrome, NK cell abnormalities, etc.)
- Coagulation abnormalities (thrombophilia, protein S/C deficiency, etc.)
- Endocrine factors (luteal phase deficiency, thyroid dysfunction, hyperprolactinemia, etc.)
- Chronic endometritis
- Balanced chromosomal translocation in one partner (requires PGT-SR technology)
2. When is IVF Suitable?
IVF is generally suitable when one of the following conditions is met:
- Confirmed embryo-derived miscarriage: Previous miscarriage tissue tested confirms chromosomal aneuploidy or segmental abnormalities, and both partners have normal karyotypes.
- Woman has adequate ovarian reserve: AMH ≥ 1.0 ng/mL, antral follicle count ≥ 5-7, sufficient to obtain enough eggs for embryo screening.
- Age within a reasonable range: Patients under 38 benefit most from PGT-A; those over 40 can still undergo screening, but the overall embryo euploidy rate is low, requiring realistic expectations.
- Other miscarriage factors have been ruled out or treated: For example, intrauterine adhesions have been surgically removed, antiphospholipid syndrome is controlled with medication, thyroid function is normalized, etc.
▸ Key point for doctors' judgment: Whether IVF is suitable depends on whether the cause of miscarriage falls within the scope of what IVF can solve and whether the patient's fertility conditions support IVF success. Both are indispensable.
3. When is Direct IVF Not Recommended?
In the following situations, it is not advisable to start an IVF cycle directly; the primary issue needs to be addressed first:
- Untreated uterine structural abnormalities: Intrauterine adhesions, septate uterus, submucosal fibroids, etc., require hysteroscopic surgery for correction first.
- Uncontrolled immune or coagulation issues: For example, positive antiphospholipid antibodies without medication, or untreated thrombophilia, still carry a high risk of miscarriage after direct transfer.
- Unassessed balanced chromosomal translocation in one partner: This condition requires PGT-SR technology; conventional PGT-A cannot fully solve the problem.
- Severely diminished ovarian reserve: AMH < 0.5 ng/mL, egg yield may be insufficient, leading to a high risk of having no embryos available for transfer after screening.
- Recurrent miscarriage without systematic etiological investigation: Direct IVF may miss key causes, leading to another miscarriage after transfer.
⚠ Common misconception: Some patients believe that "IVF can screen embryos, so regardless of the cause of miscarriage, third-generation IVF can solve it." In reality, if the cause is maternal immune attack or uterine environment issues, even chromosomally normal embryos may still miscarry after transfer. Systematic investigation is a prerequisite.
4. Common Etiological Investigations for Recurrent Pregnancy Loss
Before deciding whether to undergo IVF, it is recommended to complete the following tests to clarify the cause of miscarriage:
| Test Category | Specific Items | Explanation |
|---|---|---|
| Embryo factors | Karyotype analysis of miscarriage tissue + Chromosomal microarray (CMA) |
Determines if miscarriage is caused by embryo chromosomal abnormalities; key basis for choosing PGT-A |
| Genetic (both partners) | Peripheral blood karyotype analysis + Carrier screening for thalassemia/deafness, etc. |
Rules out structural abnormalities like balanced translocation, Robertsonian translocation |
| Uterine structure | Hysteroscopy + 3D vaginal ultrasound |
Rules out intrauterine adhesions, septum, polyps, fibroids, etc. |
| Immune factors | 3 antiphospholipid antibodies + Blocking antibodies, NK cells, T cell subsets |
Antiphospholipid syndrome is the most common treatable immune cause of miscarriage |
| Coagulation function | Protein S, Protein C, Antithrombin III + Thrombophilia gene screening (e.g., Factor V Leiden) |
Thrombophilia leads to placental microthrombi, causing miscarriage |
| Endocrine | Thyroid function (5 items), Sex hormones (6 items), OGTT, Vitamin D | Thyroid dysfunction, hyperprolactinemia, insulin resistance are all associated with miscarriage |
| Endometrium | Chronic endometritis CD138 immunohistochemistry + Endometrial microbiome test (optional) |
Chronic endometritis is a hidden cause of recurrent implantation failure and early miscarriage |
The above tests are recommended to be completed at a reproductive medicine center or a specialized recurrent miscarriage clinic. Test packages may vary slightly between hospitals, but core items should cover the six major aspects: embryo, genetics, uterus, immunity, coagulation, and endocrinology.
5. Actual Value and Limitations of PGT-A Technology
PGT-A (Preimplantation Genetic Testing for Aneuploidy) is currently the main technology used to reduce miscarriages caused by embryonic factors. Its core value is to screen for embryos with a normal number of chromosomes before transfer, avoiding miscarriage or implantation failure due to aneuploidy.
Actual value:
- For women aged ≥ 35 with a history of miscarriage due to chromosomal abnormalities, PGT-A can reduce the miscarriage rate by approximately 50%.
- For patients with recurrent miscarriage where other factors have been ruled out, PGT-A can help determine if embryonic factors are predominant.
- Reduces the number of dilation and curettage (D&C) procedures due to recurrent miscarriage, protecting the endometrium.
Limitations:
- PGT-A requires retrieving 5-15 or more eggs to have a certain probability of obtaining a euploid embryo. Patients with poor ovarian reserve may have no embryos available for transfer.
- PGT-A cannot detect microdeletions/microduplications (requires CMA) and cannot detect single-gene disorders (requires PGT-M).
- PGT-A carries a 2-5% risk of mosaicism or false positive/false negative results; it cannot guarantee 100% embryo normality.
- PGT-A does not address maternal immune, coagulation, or uterine issues; pregnancy support treatment is still needed after transfer.
▸ Practitioner observation: In clinical practice, about 30-40% of patients with recurrent miscarriage, after systematic investigation, are found to have immune or coagulation factors as the main cause rather than embryonic factors. For these patients, the value of PGT-A is limited, and the focus should be on immunotherapy and anticoagulation therapy. Blindly undergoing third-generation IVF not only increases financial burden but may also delay correct treatment.
6. Considerations for Different Age Groups
| Age Group | Main Factors for Miscarriage | IVF Strategy Focus |
|---|---|---|
| ≤ 35 years | Chromosomal abnormalities account for about 50-55%; immune/coagulation/uterine factors also need investigation | Prioritize systematic etiological investigation; if embryonic factor, PGT-A is highly beneficial; egg and embryo counts are usually sufficient |
| 36-39 years | Chromosomal abnormality rate increases to 60-70%; ovarian reserve begins to decline | PGT-A screening is valuable; but monitor AMH and antral follicle count to avoid insufficient egg yield |
| 40-42 years | Chromosomal abnormality rate reaches 75-85%; aneuploidy rate significantly increases | PGT-A can still screen, but egg yield per cycle is low; may require 2-3 cycles to accumulate embryos; have realistic expectations for success |
| ≥ 43 years | Chromosomal abnormality rate > 90%; egg quality declines sharply | Probability of obtaining a euploid embryo after PGT-A is extremely low; focus on assessing ovarian reserve and consider alternatives like egg donation |
IVF strategies vary significantly across age groups. The core is balancing the proportion of miscarriage causes attributed to embryonic factors with the patient's own ovarian reserve to support embryo screening.
7. Details Most Easily Overlooked
In the diagnosis and treatment of recurrent miscarriage, the following details are often overlooked:
- Sending miscarriage tissue for testing: Many patients do not have embryo chromosomal analysis after miscarriage, making it impossible to distinguish between embryonic and maternal issues, leaving subsequent treatment directionless. It is recommended to test after each miscarriage.
- Karyotype analysis of both partners: For couples with recurrent miscarriage, both partners need karyotype analysis, not just the woman. Balanced translocation carriers often appear normal but have a very high risk of miscarriage.
- Chronic endometritis: Routine ultrasound and hysteroscopic morphological examination may miss it; CD138 immunohistochemical staining is needed. About 30% of patients with recurrent miscarriage have chronic endometritis.
- Vitamin D deficiency: Vitamin D levels are related to immune regulation and embryo implantation but are often overlooked. Testing and supplementation to normal range are recommended.
- Male factor: Elevated sperm DNA fragmentation index (DFI) is associated with recurrent miscarriage but cannot be detected by routine semen analysis. Sperm DFI testing is recommended.
8. Common Cognitive Misconceptions
Misconception 1: Recurrent miscarriage is always the woman's problem.
In reality, chromosomal translocations in either partner, elevated sperm DFI in the male, or male carrier of genetic disease genes can all cause miscarriage. Examining both partners is the principle.
Misconception 2: Third-generation IVF can definitely solve recurrent miscarriage.
PGT-A can only screen for chromosomally normal embryos but cannot resolve immune attacks, coagulation abnormalities, or uterine environment issues. Some patients still miscarry after third-generation IVF precisely because non-embryonic factors were ignored.
Misconception 3: If you do IVF, you don't need to investigate the cause of miscarriage.
On the contrary, systematic investigation before IVF can improve IVF success rates and avoid repeated implantation failure. It is recommended to investigate first before starting a cycle.
Misconception 4: The more miscarriages, the greater the necessity for IVF.
A higher number of miscarriages does indicate a need for intervention, but the intervention method should target the cause. If it is an immune or coagulation issue, treating the primary condition may lead to successful natural pregnancy, and IVF may not be necessary.
9. IVF Process and Timeline in China
If it is determined after evaluation that IVF is needed, the general process for third-generation IVF (PGT-A) in China is as follows:
- Pre-treatment tests (1-2 months): Both partners complete pre-operative tests, including infectious diseases, chromosomes, semen analysis, ovarian reserve assessment, etc. Patients with recurrent miscarriage also need to complete the etiological investigations mentioned above.
- File creation and protocol formulation (0.5-1 month): The reproductive center doctor formulates an ovarian stimulation protocol based on age, AMH, and medical history.
- Ovarian stimulation (10-14 days): Typically uses antagonist or long protocol, daily injections of gonadotropins, monitored by ultrasound and hormone levels.
- Egg retrieval surgery (30 minutes): Transvaginal ultrasound-guided follicle aspiration under intravenous anesthesia; patient can be discharged after 2-4 hours of observation.
- Embryo culture and biopsy (5-7 days): Embryos are cultured to blastocyst stage (day 5-6), and trophectoderm biopsy is performed.
- PGT-A testing (2-4 weeks): Biopsied cells are sent for genetic sequencing to detect chromosomal aneuploidy. Embryos are frozen during the waiting period.
- Preparation for transfer (1-2 months): Endometrial preparation using natural cycle or hormone replacement cycle, depending on endometrial status.
- Embryo transfer (5-10 minutes): The screened euploid embryo is transferred into the uterine cavity under ultrasound guidance.
- Post-transfer medication and pregnancy test (12-14 days): Luteal phase support medication is given; blood HCG is tested 12-14 days after transfer.
The entire process from starting the cycle to transfer typically takes 3-5 months. If embryo accumulation (multiple egg retrievals) is involved, the time will be longer.
10. Doctor's Advice
▸ My advice for patients with recurrent miscarriage:
- First complete a systematic etiological investigation before deciding whether to do IVF.
- If miscarriage is confirmed to be caused by embryo chromosomal factors and ovarian reserve allows, PGT-A is a reasonable choice.
- If immune, coagulation, uterine, or endocrine issues exist, treat them specifically first, then evaluate the need for IVF.
- Age is an important variable. For those over 35, it is not recommended to repeatedly attempt natural pregnancy without testing; each additional miscarriage may prolong the time to eventual success.
- Choose a reproductive center with a specialized recurrent miscarriage clinic or qualifications for third-generation IVF. The doctor's experience and the center's laboratory level directly affect outcomes.
- Maintain realistic expectations for success rates, especially for patients over 40. After PGT-A screening, the live birth rate per transfer cycle is about 30-45%, not 100%.
Recurrent miscarriage is a complex issue requiring systematic investigation and individualized treatment. IVF is one technological tool, but not a universal solution. Identifying the cause, treating accordingly, and choosing the right technology are key to maximizing the chance of success.
⚠ Risk reminder: Any IVF technology carries certain risks, including ovarian hyperstimulation syndrome (OHSS) during stimulation, bleeding or infection risk during egg retrieval, loss during embryo freezing and thawing, and the limitations and potential errors of PGT-A testing. Patients with recurrent miscarriage themselves have a higher pregnancy risk; even after transferring a euploid embryo, there is still a miscarriage rate of about 10-15%. It is recommended to make an individualized treatment plan with your reproductive doctor after being fully informed and understanding the risks.
Key Term Explanations:
PGT-A: Preimplantation Genetic Testing for Aneuploidy, used to screen for embryos with a normal number of chromosomes.
AMH: Anti-Müllerian hormone, a core indicator for assessing ovarian reserve.
DFI: DNA fragmentation index, assesses sperm DNA integrity.
Recurrent pregnancy loss: Two or more consecutive pregnancy failures; clinically, three is often used as the diagnostic threshold.
Euploid: An embryo state with a normal number of chromosomes (46).
Comments (0)